IDYA IDEAYA Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1676725 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-70.1%
TTM net income YoY-143.0%
TTM EPS YoY-71.4%
Revenue 3-yr CAGR-37.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,671.1%
Net margin-3,921.1%
FCF margin-3,592.0%
EBITDA margin-4,637.0%
Returns
ROE-32.7%
ROA-31.0%
ROIC (approx.)-35.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets5.8%
Debt / equity0.00x
Current ratio14.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-3.0%
Payout ratio—
Capex / revenue55.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $218.71M | $7.00M | $23.39M | $50.93M | $27.94M |
| R&D expense | $314.70M | $294.67M | $129.51M | $89.54M | $58.16M |
| SG&A expense | $63.32M | $39.30M | $28.31M | $23.90M | $20.05M |
| Operating income | -$159.31M | -$326.98M | -$134.43M | -$62.50M | -$50.27M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$113.70M | -$274.48M | -$112.96M | -$58.66M | -$49.76M |
| EBITDA | -$156.61M | -$324.59M | -$131.95M | -$60.40M | -$48.54M |
| EPS (basic) | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 |
| EPS (diluted) | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 |
| Weighted avg. shares (diluted) | 88.49M | 81.68M | 57.52M | 41.44M | 35.25M |
| Balance sheet | |||||
| Cash & equivalents | $112.83M | $85.18M | $157.02M | $68.74M | $92.15M |
| Short-term investments | $526.56M | $591.94M | $368.10M | $296.20M | $154.72M |
| Receivables | — | $3,000 | $18,000 | $211,000 | $1.10M |
| Current assets | $666.73M | $689.71M | $532.63M | $370.45M | $251.00M |
| PP&E, net | $8.22M | $8.97M | $6.16M | $6.51M | $4.76M |
| Total assets | $1.11B | $1.12B | $649.32M | $387.97M | $381.35M |
| Current liabilities | $58.81M | $46.07M | $27.10M | $31.72M | $45.16M |
| Total liabilities | $86.39M | $64.94M | $28.23M | $38.51M | $79.83M |
| Shareholders' equity | $1.02B | $1.06B | $621.09M | $349.45M | $301.51M |
| Shares outstanding | 87.80M | 86.50M | 65.04M | 48.19M | 38.53M |
| Cash flow statement | |||||
| Operating cash flow | -$71.10M | -$247.58M | -$115.22M | -$87.17M | -$55.78M |
| Capital expenditure | $2.37M | $3.86M | $2.37M | $3.44M | $2.64M |
| Free cash flow | -$73.47M | -$251.44M | -$117.59M | -$90.62M | -$58.42M |
| Investing cash flow | $69.98M | -$502.56M | -$158.46M | -$33.40M | -$69.67M |
| Financing cash flow | $29.78M | $677.55M | $362.72M | $97.17M | $145.45M |
| Depreciation & amortization | $2.70M | $2.39M | $2.48M | $2.10M | $1.73M |
| Stock-based compensation | $46.12M | $34.75M | $18.49M | $11.63M | $8.24M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.